{"gene":"ENHO","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2008,"finding":"ENHO encodes a secreted protein called adropin (76 amino acids) expressed in liver and brain. Liver Enho expression is regulated by nutrition (increased by high-fat diet acutely, decreased by fasting and diet-induced obesity). Transgenic overexpression or systemic adropin treatment in diet-induced obese mice attenuated hepatosteatosis and insulin resistance, and adropin regulated expression of hepatic lipogenic genes and adipose tissue PPARγ.","method":"Transgenic overexpression, systemic peptide treatment, gene expression analysis in mouse models","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — original discovery paper with multiple orthogonal methods (transgenic OE, peptide treatment, gene expression), replicated by subsequent independent studies","pmids":["19041763"],"is_preprint":false},{"year":2016,"finding":"Adropin reduces paracellular permeability of brain endothelial cells exposed to ischemia-like conditions (hypoxia/low glucose) by inhibiting the ROCK–MLC2 signaling pathway. Adropin treatment concentration-dependently reduced MLC2 phosphorylation and attenuated Rho-associated kinase (ROCK) activity without protecting tight junction proteins (occludin, VE-cadherin) or reducing VEGF.","method":"In vitro BBB model (RBE4 rat brain endothelial cells), FITC-dextran permeability assay, ROCK activity assay, Western blot for MLC2 phosphorylation","journal":"Peptides","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean in vitro mechanistic dissection with multiple readouts in a single lab","pmids":["27020249"],"is_preprint":false},{"year":2017,"finding":"Adropin knockout (AdrKO) mice exhibited reduced eNOS phosphorylation at Ser1177, impaired glycosphingolipid biosynthesis, adipocyte infiltration, loss of Treg cells, and developed fatty pancreas and type 2 diabetes, establishing that adropin deficiency drives these metabolic and immune phenotypes. A Cys56Trp mutation in ENHO was identified in human patients with fatty pancreas and T2DM.","method":"Adropin knockout mice (C57BL/6J), Western blot for phospho-eNOS, metabolic phenotyping, Treg quantification, human ENHO sequencing","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse model with multiple mechanistic readouts and human genetic validation, single lab","pmids":["28837146"],"is_preprint":false},{"year":2017,"finding":"Hepatic Enho expression is rhythmically controlled by the biological clock, peaking during feeding (dark phase) via transcriptional activation by RORα/γ, and suppressed during the rest phase by Rev-erb. ROR inverse agonists (SR1001), 7-oxygenated sterols (7-β-hydroxysterol, 7-ketocholesterol), and the Rev-erb agonist SR9009 suppress ENHO expression in cultured HepG2 cells. High-cholesterol diets suppress hepatic adropin expression, but adropin overexpression does not prevent hypercholesterolemia.","method":"In silico expression analysis, cultured human HepG2 cells treated with nuclear receptor ligands, animal dietary intervention, nonhuman primate plasma adropin profiling","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (cell culture, animal models, NHP) in single publication establishing circadian/nuclear receptor regulation","pmids":["29331507"],"is_preprint":false},{"year":2016,"finding":"Adropin deficiency (AdrKO mice) leads to reduced eNOS (Ser1177) and Akt1 (Ser473) phosphorylation and loss of Treg cells, and homo- and heterozygous null mice exhibit MPO-ANCA-associated pulmonary alveolar hemorrhage. Six ENHO mutations (p.Ser43Thr, Cys56Trp) were identified in human MPO-ANCA vasculitis patients.","method":"Adropin knockout mice, Western blot for phospho-eNOS/Akt1, Treg analysis, human ENHO sequencing in 152 patients","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse with mechanistic phosphorylation readouts plus human genetic data, single lab","pmids":["27333037"],"is_preprint":false},{"year":2018,"finding":"EOGT (epidermal growth factor domain-specific O-linked GlcNAc transferase) positively regulates ENHO/adropin expression in decidualizing human endometrial stromal cells; EOGT knockdown caused the largest reduction in ENHO among a network of decidual genes. Obesity inversely correlates with both EOGT and ENHO expression in endometrium.","method":"EOGT siRNA knockdown in primary human endometrial stromal cells, RNA expression profiling, endometrial biopsy analysis","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct knockdown experiment identifying upstream regulator of ENHO, single lab with in vitro and human tissue validation","pmids":["29244071"],"is_preprint":false},{"year":2019,"finding":"Adropin stimulates proliferation of 3T3-L1 cells and rat primary preadipocytes via ERK1/2 and AKT signaling, and reduces lipid accumulation and expression of pro-adipogenic genes, suppressing differentiation of preadipocytes into mature fat cells.","method":"3T3-L1 cell and rat primary preadipocyte cultures, BrdU proliferation assay, Oil Red O lipid staining, Western blot for ERK1/2 and AKT phosphorylation, real-time PCR for adipogenic gene expression","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean in vitro mechanistic dissection with multiple readouts in two cell models, single lab","pmids":["31400396"],"is_preprint":false},{"year":2020,"finding":"GPR19 is expressed in human HAC15 adrenocortical carcinoma cells and mediates adropin signaling. Adropin decreases expression of steroidogenic genes (StAR, CYP11A1), leading to reduced cortisol and aldosterone biosynthesis via the TGF-β signaling pathway acting through a transactivation mechanism. Adropin stimulates HAC15 cell proliferation via ERK1/2 and AKT signaling pathways. GPR19 expression is not regulated by ACTH, forskolin, or adropin itself.","method":"HAC15 cell culture, GPR19 expression analysis, steroidogenesis assays (ELISA for cortisol/aldosterone), whole transcriptome study, TGF-β receptor kinase inhibitor rescue experiment, specific intracellular inhibitors for ERK1/2 and AKT","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods in single lab identifying receptor, pathway, and functional outcomes","pmids":["33133015"],"is_preprint":false},{"year":2020,"finding":"STAT3 transcriptionally regulates ENHO/adropin expression in hepatocytes. High glucose increased STAT3 phosphorylation and Enho mRNA in HepG2 cells; pharmacological STAT3 inhibition (Stattic) or STAT3 siRNA knockdown abolished high-glucose-induced Enho upregulation. In diabetic rats, elevated plasma adropin and hepatic Enho expression were reduced by insulin or phloridzin treatment coinciding with reduced STAT3 activity.","method":"HepG2 cells under high glucose, STAT3 inhibitor (Stattic), STAT3 siRNA knockdown, real-time PCR for Enho mRNA, Western blot for pSTAT3/STAT3, streptozotocin diabetic rat model","journal":"Diabetes, metabolic syndrome and obesity : targets and therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic (siRNA) inhibition of STAT3 with consistent results in vitro and in vivo, single lab","pmids":["32636661"],"is_preprint":false},{"year":2020,"finding":"Adropin stimulates proliferation of rat brown preadipocytes and suppresses their differentiation into mature brown adipocytes, reducing mRNA expression of adipogenic genes (C/ebpα, C/ebpβ, Pgc1α, Pparγ, Prdm16), suppressing UCP1 protein, and reducing intracellular lipid content.","method":"Rat primary brown preadipocyte isolation, BrdU incorporation, real-time PCR, Western blot, Oil Red O staining, glycerol/free fatty acid release assays","journal":"Archives of biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal readouts in primary cells, single lab, consistent with findings in white preadipocytes","pmids":["32798458"],"is_preprint":false},{"year":2022,"finding":"Genetic deletion of Enho significantly increased infarct volume and worsened neurological function following transient middle cerebral artery occlusion in aged mice, while adropin overexpression dramatically reduced stroke volume. Postischemic adropin treatment reduced blood-brain barrier damage by reducing MMP-9 and preserving tight junction proteins.","method":"Enho knockout and overexpression mice, transient MCAO model, TTC staining, Western blot for MMP-9 and tight junction proteins, behavioral tests","journal":"Stroke","confidence":"High","confidence_rationale":"Tier 2 / Strong — both loss-of-function (KO) and gain-of-function (OE and peptide treatment) with consistent mechanistic readouts replicated across multiple experimental arms","pmids":["36305313"],"is_preprint":false},{"year":2022,"finding":"Hepatic adropin/Enho expression is regulated by estrogen; 17β-estradiol tripled Enho expression in BNL 1 ME liver cells with increased adropin secretion. Ovariectomy reduced hepatic Enho expression in mice, and open-access datasets confirmed estrogen-dependent ERα binding to Enho. Adropin treatment in OVX mice reversed adverse adipokine gene expression in visceral adipose tissue.","method":"Ovariectomy mouse model, in vitro 17β-estradiol treatment of liver cells, RNA-seq, ELISA for adropin, open-access ChIP dataset for ERα binding, adropin peptide treatment","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo experiments with ChIP confirmation of ERα binding to Enho, single lab","pmids":["35364299"],"is_preprint":false},{"year":2023,"finding":"Adropin inhibits EndMT (endothelial-to-mesenchymal transition) in HUVECs via the TGF-β/Smad2/3 signaling pathway. In vivo, adropin treatment inhibited atherosclerosis progression in ApoE-/-/Enho-/- mice. Adropin decreased TGF-β1 and TGF-β2 expression and suppressed Smad2/3 phosphorylation; these effects were reversed by TGF-β plasmid transfection.","method":"ApoE-/-/Enho-/- double knockout mice, HFD atherosclerosis model, Oil Red O staining, HUVEC culture with H2O2-induced EndMT, TGF-β plasmid transfection rescue, Western blot for Smad2/3 phosphorylation, immunofluorescence","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic rescue experiment and in vivo double KO model, single lab","pmids":["37903785"],"is_preprint":false},{"year":2024,"finding":"TGFβ reduces adropin/ENHO expression in fibroblasts via a JNK-dependent mechanism. Restoration of adropin signaling with bioactive adropin34-76 peptide inhibits TGFβ-induced fibroblast activation and fibrotic remodeling. Knockdown of GPR19 (adropin receptor) abrogates the antifibrotic effects. RNA-seq and ChIP-seq showed adropin34-76 deactivates GLI1-dependent profibrotic transcriptional networks. These mechanisms were confirmed in primary human dermal fibroblasts, 3D skin equivalents, mouse models (bleomycin and sclGvHD), and precision-cut human skin slices.","method":"GPR19 siRNA knockdown, RNA-seq, ChIP-seq, in vitro fibroblast cultures, 3D skin equivalents, bleomycin and sclGvHD mouse models, precision-cut human skin slices, JNK inhibitor experiments","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (RNA-seq, ChIP-seq, receptor KD, multiple in vivo models, human tissue), replicated across multiple experimental systems in one rigorous study","pmids":["38536934"],"is_preprint":false},{"year":2023,"finding":"Adropin deficiency (Enho-/- mice) leads to spontaneous colitis and an imbalance in macrophage polarization (increased M1, decreased M2) in colon and mesenteric tissues. In vitro, adropin regulates lipid metabolism of macrophages through PPARγ, promoting repolarization from M1 to M2. This was demonstrated by combined RNA-seq and metabolomics analysis in RAW264.7 macrophages.","method":"Enho-/- (AdrKO) mice, TNBS-induced colitis model, RNA-seq and metabolomics of RAW264.7 macrophages, macrophage polarization assays","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockout mouse with in vitro mechanistic follow-up using two omics approaches, single lab","pmids":["37688913"],"is_preprint":false},{"year":2023,"finding":"Low-dose adropin (<100 ng/mL) directly increases mitochondrial reactive oxygen species in macrophages to activate the inflammasome, promoting M1 macrophage polarization. High-dose adropin enhances CPT1α expression in macrophages. ENHO-/- mice had fewer M1 macrophages, and ENHO-/- macrophages were resistant to M1 induction. ENHO gene transfection into MC38 colon cancer cells inhibited tumor growth in vivo with increased M1 macrophages.","method":"Ex vivo macrophage adropin treatment, mitochondrial ROS measurement, inflammasome activation assays, ENHO-/- mice, ENHO gene transfection into MC38 tumor cells, in vivo tumor models","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both in vitro mechanistic data and KO mouse validation with multiple readouts, single lab","pmids":["37904094"],"is_preprint":false},{"year":2022,"finding":"Myricetin increases circulating adropin in type-1 diabetic rats through GLP-1 receptor activation leading to β-endorphin secretion that activates peripheral μ-opioid receptors; GLP-1 receptor antagonist blocked myricetin-induced adropin increases. In HepG2 cells, myricetin-induced GLP-1 receptor activation modulated Enho expression.","method":"Streptozotocin diabetic rat model, GLP-1 receptor antagonist treatment, adrenalectomy, ELISA for plasma adropin and β-endorphin, qPCR for Enho in HepG2 cells","journal":"Pharmaceuticals (Basel, Switzerland)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological intervention study with indirect pathway inferences, single lab, mechanistic chain not directly confirmed","pmids":["35215286"],"is_preprint":false},{"year":2023,"finding":"In mouse testis, adropin alone inhibits testosterone synthesis by suppressing P450-SCC, 3β-HSD, and 17β-HSD expression, while adropin combined with insulin stimulates testicular testosterone synthesis by increasing GPR19, IR, StAR, P450-SCC, 3β-HSD, and 17β-HSD expression. Adropin promotes germ cell survival and proliferation by upregulating PCNA, Bcl2, and pERK1/2. GPR19 was identified on pachytene spermatocytes and Leydig cells.","method":"Immunohistochemistry for adropin/GPR19 in mouse testis, in vitro testicular slice culture, Western blot for steroidogenic enzymes and signaling proteins, Enho mRNA expression","journal":"Journal of experimental zoology. Part A, Ecological and integrative physiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — in vitro testicular slice culture with protein expression readouts, single lab, no receptor-specific antagonist controls","pmids":["37902254"],"is_preprint":false},{"year":2025,"finding":"Adropin exerts protective effects in LPS-induced septic cardiomyopathy by activating the Nrf2/ARE signaling pathway, increasing antioxidant proteins (NQO1, GPX1, Nrf2), reducing ROS, and suppressing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and apoptosis (reduced Bax, increased Bcl-2). The Nrf2 inhibitor ML385 blocked adropin's antioxidant effects.","method":"LPS mouse model of myocardial injury, Nrf2 inhibitor (ML385) rescue experiment, qRT-PCR, Western blot, DHE staining and flow cytometry for ROS, echocardiography","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological rescue with Nrf2 inhibitor identifies mechanistic pathway, multiple readouts, single lab","pmids":["41391279"],"is_preprint":false},{"year":2025,"finding":"Adropin promotes macrophage M2 polarization by upregulating heme oxygenase-1 (HO-1), and adropin-treated macrophage-conditioned medium induces browning of fully differentiated 3T3-L1 adipocytes. In PCOS model mice, adropin treatment reduced body weight and promoted M2 macrophage phenotype and white adipose tissue browning.","method":"RAW264.7 macrophage HO-1 expression analysis, conditioned medium transfer to 3T3-L1 adipocytes, letrozole-induced PCOS mouse model, in vivo adropin injection","journal":"International immunopharmacology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — conditioned medium approach is indirect, single lab, HO-1 mechanistic link not confirmed by loss-of-function","pmids":["39933360"],"is_preprint":false},{"year":2025,"finding":"ENHO/adropin transcriptional co-expression structures across human tissues revealed that liver ENHO expression co-regulates skeletal muscle mitochondrial function (confirmed in liver-specific knockout mice). Within-liver ENHO expression reflects lipoprotein metabolism (APOC1, APOA1). Statin treatment (which increases hepatic cholesterol efflux) reduces plasma adropin levels. The ENHO gene contains RORE elements, linking it to circadian/ROR regulation across tissues.","method":"Transcriptomic correlation analysis across human tissues (GD-CAT), liver-specific knockout mice, plasma adropin/lipoprotein correlation, statin-treatment experiment","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — liver-specific KO confirms functional co-regulation; correlational analyses and statin experiment in single publication","pmids":["40578684"],"is_preprint":false},{"year":2019,"finding":"Hepatic ENHO expression in nonhuman primates associates with genes involved in glucose and lipid metabolism, and co-regulated genes are enriched for epigenetic silencing by histone H3K27 trimethylation and neural function pathways. Low plasma adropin concentrations predict greater weight gain and metabolic dysregulation (hyperglycemia, elevated APOC3/triglycerides) during high-sugar diet consumption.","method":"In silico expression profiling (diurnal transcriptome atlas GSE98965), unsupervised hierarchical clustering, Gene Ontology analysis, dietary intervention in 59 adult male rhesus macaques","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — primarily bioinformatic with correlational animal intervention; no direct mechanistic experiment on ENHO protein function","pmids":["30988006"],"is_preprint":false}],"current_model":"ENHO encodes adropin, a secreted peptide hormone (active form adropin34-76) that signals through the GPR19 receptor to regulate energy homeostasis: adropin is transcriptionally controlled by circadian nuclear receptors (RORα/γ activates, Rev-erb represses), STAT3, estrogen (ERα), and nutrients (high-fat/sugar diet, cholesterol); it attenuates hepatic lipogenesis and insulin resistance, reduces blood-brain barrier permeability via ROCK–MLC2 inhibition, suppresses preadipocyte differentiation via ERK1/2/AKT, inhibits fibroblast activation by deactivating GLI1-dependent profibrotic transcription downstream of GPR19 (counteracting TGFβ–JNK-mediated ENHO suppression), promotes macrophage M1→M2 repolarization through PPARγ-mediated lipid metabolism, and protects against ischemic stroke and septic cardiomyopathy partly through eNOS phosphorylation and Nrf2/ARE antioxidant pathways."},"narrative":{"mechanistic_narrative":"ENHO encodes adropin, a secreted peptide hormone (active form adropin34-76) that regulates energy homeostasis and protects against metabolic and inflammatory tissue injury [PMID:19041763, PMID:38536934]. Hepatic Enho expression is nutritionally and hormonally gated: it is induced acutely by high-fat diet and reduced by fasting and diet-induced obesity [PMID:19041763], driven rhythmically by the circadian nuclear receptors RORα/γ (activating) and Rev-erb (repressing) [PMID:29331507], and additionally controlled by STAT3 under high glucose [PMID:32636661], by estrogen via ERα binding to Enho [PMID:35364299], and by EOGT in decidualizing endometrium [PMID:29244071]; high-cholesterol diet and statin-driven cholesterol efflux suppress it [PMID:29331507, PMID:40578684]. Functionally, adropin overexpression or peptide treatment attenuates hepatosteatosis and insulin resistance and reprograms hepatic lipogenic and adipose PPARγ gene expression [PMID:19041763], and liver ENHO co-regulates skeletal-muscle mitochondrial function [PMID:40578684]. Adropin signals through the receptor GPR19 [PMID:33133015, PMID:38536934]: it deactivates GLI1-dependent profibrotic transcription to block TGFβ-driven fibroblast activation, counteracting JNK-mediated suppression of its own gene [PMID:38536934], suppresses preadipocyte differentiation while stimulating proliferation via ERK1/2 and AKT [PMID:31400396, PMID:32798458], and reprograms macrophage polarization through PPARγ-linked lipid metabolism [PMID:37688913]. It is cytoprotective in ischemic stroke, where Enho deletion enlarges infarcts and adropin preserves blood-brain barrier integrity by inhibiting ROCK–MLC2 signaling and reducing MMP-9 [PMID:27020249, PMID:36305313], and in septic cardiomyopathy via the Nrf2/ARE antioxidant axis [PMID:41391279]. Loss-of-function in mice produces fatty pancreas, type 2 diabetes, reduced eNOS Ser1177 phosphorylation, and immune dysregulation, and ENHO coding mutations were identified in human patients with fatty pancreas/T2DM and with MPO-ANCA vasculitis [PMID:28837146, PMID:27333037].","teleology":[{"year":2008,"claim":"Established that ENHO encodes a secreted, nutritionally regulated peptide hormone (adropin) controlling hepatic lipid metabolism and insulin sensitivity, defining the gene's core physiological role.","evidence":"Transgenic overexpression, systemic peptide treatment, and hepatic/adipose gene expression analysis in diet-induced obese mice","pmids":["19041763"],"confidence":"High","gaps":["Receptor and direct signaling mechanism not identified","Tissue source of circulating adropin beyond liver not resolved"]},{"year":2016,"claim":"Identified a vascular-protective mechanism distinct from metabolic action, showing adropin reduces brain endothelial permeability under ischemic conditions via ROCK–MLC2 inhibition.","evidence":"In vitro RBE4 rat brain endothelial BBB model, FITC-dextran permeability, ROCK activity assay, MLC2 phospho-Western blot","pmids":["27020249"],"confidence":"Medium","gaps":["Receptor mediating the effect not defined","No in vivo confirmation in this study","Did not affect tight junction proteins or VEGF, leaving upstream coupling unclear"]},{"year":2016,"claim":"Linked adropin deficiency to eNOS/Akt signaling and immune dysregulation, and connected ENHO coding variants to human autoimmune vasculitis.","evidence":"Adropin knockout mice with phospho-eNOS/Akt1 Westerns, Treg analysis, and ENHO sequencing in 152 MPO-ANCA patients","pmids":["27333037"],"confidence":"Medium","gaps":["Causality of human variants not functionally tested","Mechanism linking adropin loss to autoimmunity not defined"]},{"year":2017,"claim":"Demonstrated that adropin deficiency drives a metabolic-disease phenotype (fatty pancreas, T2DM) and identified a human ENHO mutation in affected patients.","evidence":"AdrKO mice with metabolic phenotyping, phospho-eNOS Western, Treg quantification, and human ENHO sequencing","pmids":["28837146"],"confidence":"Medium","gaps":["Cys56Trp mutation not functionally characterized","Single-lab phenotype"]},{"year":2017,"claim":"Defined the upstream transcriptional logic of ENHO, placing it under circadian nuclear-receptor control (ROR activation, Rev-erb repression) and sterol/cholesterol regulation.","evidence":"HepG2 cells treated with nuclear-receptor ligands, dietary intervention, and nonhuman-primate plasma profiling","pmids":["29331507"],"confidence":"Medium","gaps":["Direct RORE occupancy at the endogenous locus not shown here","Physiological consequence of rhythmicity not tested"]},{"year":2019,"claim":"Showed adropin acts directly on adipocyte precursors, stimulating proliferation via ERK1/2/AKT while suppressing adipogenic differentiation.","evidence":"3T3-L1 and rat primary preadipocyte cultures, BrdU, Oil Red O, ERK1/2/AKT Westerns, adipogenic gene qPCR","pmids":["31400396"],"confidence":"Medium","gaps":["Receptor not identified in these cells","In vivo relevance to adipose mass not tested"]},{"year":2019,"claim":"Associated hepatic ENHO with glucose/lipid metabolic gene networks and showed low plasma adropin predicts diet-induced metabolic dysregulation.","evidence":"Bioinformatic expression profiling and dietary intervention in rhesus macaques","pmids":["30988006"],"confidence":"Low","gaps":["Correlational/bioinformatic; no direct manipulation of ENHO","Causality of plasma adropin as predictor unestablished"]},{"year":2020,"claim":"Identified GPR19 as the receptor mediating adropin signaling and demonstrated adropin suppresses steroidogenesis via TGF-β transactivation while driving proliferation through ERK1/2/AKT.","evidence":"HAC15 adrenocortical cells, GPR19 expression, steroidogenesis ELISAs, transcriptomics, TGF-β kinase inhibitor and ERK/AKT inhibitor experiments","pmids":["33133015"],"confidence":"Medium","gaps":["Direct adropin–GPR19 binding not demonstrated","Generalizability of receptor coupling to other tissues not shown"]},{"year":2020,"claim":"Added STAT3 and estrogen/ERα as upstream regulators of hepatic ENHO, linking adropin output to glucose state and hormonal status.","evidence":"HepG2 high-glucose STAT3 inhibition/siRNA with diabetic rats; ovariectomy mice, 17β-estradiol on liver cells, RNA-seq, ERα ChIP datasets","pmids":["32636661","35364299"],"confidence":"Medium","gaps":["Direct STAT3 occupancy at ENHO promoter not mapped in first study","Integration of competing transcriptional inputs not resolved"]},{"year":2022,"claim":"Established a causal protective role for ENHO in ischemic stroke through both loss- and gain-of-function, acting on blood-brain barrier integrity.","evidence":"Enho knockout and overexpression mice in transient MCAO, TTC staining, MMP-9 and tight-junction Westerns, behavioral testing","pmids":["36305313"],"confidence":"High","gaps":["Receptor mediating neuroprotection not defined in vivo","Relationship to the earlier ROCK–MLC2 mechanism not directly tested"]},{"year":2023,"claim":"Revealed adropin as an immunometabolic regulator of macrophage polarization, promoting M1→M2 repolarization through PPARγ-linked lipid metabolism with dose-dependent inflammasome effects.","evidence":"Enho-/- colitis and tumor models, RNA-seq/metabolomics in RAW264.7 macrophages, mitochondrial ROS and inflammasome assays, ENHO transfection into MC38 cells","pmids":["37688913","37904094"],"confidence":"Medium","gaps":["Dose-dependent opposing effects on M1 vs M2 not mechanistically reconciled","Receptor dependence of macrophage effects not tested"]},{"year":2023,"claim":"Showed adropin restrains TGF-β/Smad2/3-driven endothelial-to-mesenchymal transition and atherosclerosis progression.","evidence":"ApoE-/-/Enho-/- mice, HUVEC EndMT model, TGF-β plasmid rescue, Smad2/3 phospho-Westerns","pmids":["37903785"],"confidence":"Medium","gaps":["Receptor not interrogated","Single-lab finding"]},{"year":2024,"claim":"Defined the antifibrotic mechanism at the transcriptional level, showing GPR19-dependent adropin34-76 deactivates GLI1 profibrotic networks while TGFβ suppresses ENHO via JNK, establishing a feedback circuit.","evidence":"GPR19 siRNA knockdown, RNA-seq, ChIP-seq, human fibroblasts, 3D skin equivalents, bleomycin/sclGvHD mouse models, precision-cut human skin slices, JNK inhibitor experiments","pmids":["38536934"],"confidence":"High","gaps":["Direct adropin–GPR19–GLI1 biochemical link not fully resolved","Translation to systemic fibrosis beyond skin not shown"]},{"year":2025,"claim":"Extended adropin's protective repertoire to septic cardiomyopathy via the Nrf2/ARE antioxidant pathway.","evidence":"LPS mouse myocardial injury, Nrf2 inhibitor (ML385) rescue, ROS staining/flow cytometry, echocardiography","pmids":["41391279"],"confidence":"Medium","gaps":["Receptor coupling to Nrf2 not defined","Single-lab finding"]},{"year":2025,"claim":"Connected hepatic ENHO to systemic mitochondrial and lipoprotein metabolism, with liver-specific knockout confirming cross-tissue muscle regulation.","evidence":"Cross-tissue transcriptomic correlation (GD-CAT), liver-specific knockout mice, plasma adropin/lipoprotein correlation, statin experiment","pmids":["40578684"],"confidence":"Medium","gaps":["Mediator of liver-to-muscle communication not identified","Correlational human data"]},{"year":null,"claim":"How a single secreted peptide acting through GPR19 produces context- and dose-dependent outcomes across metabolic, vascular, fibrotic, and immune tissues remains unresolved, as does the structural basis of adropin–GPR19 engagement.","evidence":"No direct ligand-receptor structural or binding study present in the corpus","pmids":[],"confidence":"Low","gaps":["No structural model of adropin or adropin–GPR19 complex","Mechanism reconciling opposing dose-dependent immune effects unknown","Whether all downstream pathways (ROCK, Nrf2, PPARγ, GLI1) require GPR19 untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,7,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,6,12]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,11]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[14,15]},{"term_id":"R-HSA-9909396","term_label":"Circadian clock","supporting_discovery_ids":[3,20]}],"complexes":[],"partners":["GPR19"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q6UWT2","full_name":"Adropin","aliases":["Energy homeostasis-associated protein"],"length_aa":76,"mass_kda":7.9,"function":"Involved in the regulation of glucose homeostasis and lipid metabolism","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q6UWT2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ENHO","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1165,"dependency_fraction":0.0008583690987124463},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ENHO","total_profiled":1310},"omim":[{"mim_id":"618556","title":"ENERGY HOMEOSTASIS-ASSOCIATED PROTEIN; ENHO","url":"https://www.omim.org/entry/618556"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":589.2}],"url":"https://www.proteinatlas.org/search/ENHO"},"hgnc":{"alias_symbol":["UNQ470"],"prev_symbol":["C9orf165"]},"alphafold":{"accession":"Q6UWT2","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6UWT2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q6UWT2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q6UWT2-F1-predicted_aligned_error_v6.png","plddt_mean":74.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ENHO","jax_strain_url":"https://www.jax.org/strain/search?query=ENHO"},"sequence":{"accession":"Q6UWT2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q6UWT2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q6UWT2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q6UWT2"}},"corpus_meta":[{"pmid":"19041763","id":"PMC_19041763","title":"Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.","date":"2008","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19041763","citation_count":378,"is_preprint":false},{"pmid":"32012786","id":"PMC_32012786","title":"Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32012786","citation_count":77,"is_preprint":false},{"pmid":"29331507","id":"PMC_29331507","title":"Adropin: An endocrine link between the biological clock and cholesterol homeostasis.","date":"2017","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29331507","citation_count":73,"is_preprint":false},{"pmid":"35955453","id":"PMC_35955453","title":"Adropin's Role in Energy Homeostasis and Metabolic Disorders.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35955453","citation_count":67,"is_preprint":false},{"pmid":"30988006","id":"PMC_30988006","title":"Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30988006","citation_count":54,"is_preprint":false},{"pmid":"28837146","id":"PMC_28837146","title":"Adropin deficiency worsens HFD-induced metabolic defects.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28837146","citation_count":48,"is_preprint":false},{"pmid":"29896421","id":"PMC_29896421","title":"Age-Dependent Decrease in Adropin is Associated with Reduced Levels of Endothelial Nitric Oxide Synthase and Increased Oxidative Stress in the Rat Brain.","date":"2018","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29896421","citation_count":47,"is_preprint":false},{"pmid":"31400396","id":"PMC_31400396","title":"Effects of adropin on proliferation and differentiation of 3T3-L1 cells and rat primary preadipocytes.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31400396","citation_count":45,"is_preprint":false},{"pmid":"27020249","id":"PMC_27020249","title":"Adropin reduces paracellular permeability of rat brain endothelial cells exposed to ischemia-like conditions.","date":"2016","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/27020249","citation_count":40,"is_preprint":false},{"pmid":"27546995","id":"PMC_27546995","title":"Association of Serum Adropin Concentrations with Diabetic Nephropathy.","date":"2016","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27546995","citation_count":38,"is_preprint":false},{"pmid":"31251698","id":"PMC_31251698","title":"Acute suppression of insulin resistance-associated hepatic miR-29 in vivo improves glycemic control in adult mice.","date":"2019","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31251698","citation_count":34,"is_preprint":false},{"pmid":"26435060","id":"PMC_26435060","title":"Differential Responses of Plasma Adropin Concentrations To Dietary Glucose or Fructose Consumption In Humans.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26435060","citation_count":34,"is_preprint":false},{"pmid":"36305313","id":"PMC_36305313","title":"Therapeutic Benefits of Adropin in Aged Mice After Transient Ischemic Stroke via Reduction of Blood-Brain Barrier Damage.","date":"2022","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/36305313","citation_count":32,"is_preprint":false},{"pmid":"27333037","id":"PMC_27333037","title":"Enho Mutations Causing Low Adropin: A Possible Pathomechanism of MPO-ANCA Associated Lung Injury.","date":"2016","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/27333037","citation_count":29,"is_preprint":false},{"pmid":"35456975","id":"PMC_35456975","title":"Recognition of a Novel Gene Signature for Human Glioblastoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35456975","citation_count":29,"is_preprint":false},{"pmid":"27668650","id":"PMC_27668650","title":"Adropin - physiological and pathophysiological role.","date":"2016","source":"Postepy higieny i medycyny doswiadczalnej (Online)","url":"https://pubmed.ncbi.nlm.nih.gov/27668650","citation_count":29,"is_preprint":false},{"pmid":"29244071","id":"PMC_29244071","title":"The Glycosyltransferase EOGT Regulates Adropin Expression in Decidualizing Human Endometrium.","date":"2018","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29244071","citation_count":26,"is_preprint":false},{"pmid":"33133015","id":"PMC_33133015","title":"Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33133015","citation_count":24,"is_preprint":false},{"pmid":"30514096","id":"PMC_30514096","title":"The association of serum and vitreous adropin concentrations with diabetic retinopathy.","date":"2019","source":"Annals of clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30514096","citation_count":24,"is_preprint":false},{"pmid":"38536934","id":"PMC_38536934","title":"Attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38536934","citation_count":22,"is_preprint":false},{"pmid":"27594563","id":"PMC_27594563","title":"New peptides players in metabolic disorders.","date":"2016","source":"Postepy higieny i medycyny doswiadczalnej (Online)","url":"https://pubmed.ncbi.nlm.nih.gov/27594563","citation_count":19,"is_preprint":false},{"pmid":"34366886","id":"PMC_34366886","title":"Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease.","date":"2021","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34366886","citation_count":19,"is_preprint":false},{"pmid":"35364299","id":"PMC_35364299","title":"Hepatic adropin is regulated by estrogen and contributes to adverse metabolic phenotypes in ovariectomized mice.","date":"2022","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35364299","citation_count":17,"is_preprint":false},{"pmid":"37903785","id":"PMC_37903785","title":"Adropin inhibits the progression of atherosclerosis in ApoE-/-/Enho-/- mice by regulating endothelial-to-mesenchymal transition.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37903785","citation_count":16,"is_preprint":false},{"pmid":"32636661","id":"PMC_32636661","title":"Promotion of Adropin Expression by Hyperglycemia Is Associated with STAT3 Activation in Diabetic Rats.","date":"2020","source":"Diabetes, metabolic syndrome and obesity : targets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32636661","citation_count":16,"is_preprint":false},{"pmid":"35215286","id":"PMC_35215286","title":"Myricetin Increases Circulating Adropin Level after Activation of Glucagon-like Peptide 1 (GLP-1) Receptor in Type-1 Diabetic Rats.","date":"2022","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35215286","citation_count":15,"is_preprint":false},{"pmid":"34849758","id":"PMC_34849758","title":"Bacteriophages PɸEn-CL and PɸEn-HO can eliminate MDR Enterobacter cloacae and Enterobacter hormaechei isolated from burn wound infections without toxicity for human skin cells.","date":"2021","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34849758","citation_count":13,"is_preprint":false},{"pmid":"33011220","id":"PMC_33011220","title":"Swim therapy-induced tissue specific metabolic responses in male rats.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33011220","citation_count":13,"is_preprint":false},{"pmid":"30413149","id":"PMC_30413149","title":"ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30413149","citation_count":12,"is_preprint":false},{"pmid":"36717106","id":"PMC_36717106","title":"Protective roles of adropin in neurological disease.","date":"2023","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36717106","citation_count":12,"is_preprint":false},{"pmid":"30239031","id":"PMC_30239031","title":"Association of serum adropin with the presence of atrial fibrillation and atrial remodeling.","date":"2018","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/30239031","citation_count":12,"is_preprint":false},{"pmid":"27449397","id":"PMC_27449397","title":"Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients.","date":"2016","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27449397","citation_count":11,"is_preprint":false},{"pmid":"32798458","id":"PMC_32798458","title":"Adropin stimulates proliferation but suppresses differentiation in rat primary brown preadipocytes.","date":"2020","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/32798458","citation_count":11,"is_preprint":false},{"pmid":"39906123","id":"PMC_39906123","title":"Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39906123","citation_count":11,"is_preprint":false},{"pmid":"28076839","id":"PMC_28076839","title":"Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28076839","citation_count":9,"is_preprint":false},{"pmid":"38766744","id":"PMC_38766744","title":"Meiotic transcriptional reprogramming mediated by cell-cell communications in humans and mice revealed by scATAC-seq and scRNA-seq.","date":"2024","source":"Zoological research","url":"https://pubmed.ncbi.nlm.nih.gov/38766744","citation_count":8,"is_preprint":false},{"pmid":"37904094","id":"PMC_37904094","title":"Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression.","date":"2023","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37904094","citation_count":8,"is_preprint":false},{"pmid":"26055914","id":"PMC_26055914","title":"Molecular cloning, characterization and expression of the energy homeostasis-associated gene in piglet.","date":"2015","source":"Journal of Zhejiang University. Science. B","url":"https://pubmed.ncbi.nlm.nih.gov/26055914","citation_count":8,"is_preprint":false},{"pmid":"31775661","id":"PMC_31775661","title":"Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis patients: a cross-sectional study.","date":"2019","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/31775661","citation_count":7,"is_preprint":false},{"pmid":"34066943","id":"PMC_34066943","title":"Effect of Long-Term Continuous Light Exposure and Western Diet on Adropin Expression, Lipid Metabolism, and Energy Homeostasis in Rats.","date":"2021","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/34066943","citation_count":6,"is_preprint":false},{"pmid":"34316188","id":"PMC_34316188","title":"Optimal therapeutic adropin dose intervention in mice and rat animal models: A systematic review.","date":"2021","source":"Veterinary world","url":"https://pubmed.ncbi.nlm.nih.gov/34316188","citation_count":6,"is_preprint":false},{"pmid":"36830976","id":"PMC_36830976","title":"Energy Homeostasis-Associated (Enho) mRNA Expression and Energy Homeostasis in the Acute Stress Versus Chronic Unpredictable Mild Stress Rat Models.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36830976","citation_count":5,"is_preprint":false},{"pmid":"40340725","id":"PMC_40340725","title":"Isoform-resolution single-cell RNA sequencing reveals the transcriptional panorama of adult Baoshan pig testis cells.","date":"2025","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40340725","citation_count":5,"is_preprint":false},{"pmid":"37902254","id":"PMC_37902254","title":"Adropin may promote insulin stimulated steroidogenesis and spermatogenesis in adult mice testes.","date":"2023","source":"Journal of experimental zoology. Part A, Ecological and integrative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37902254","citation_count":5,"is_preprint":false},{"pmid":"39674635","id":"PMC_39674635","title":"Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease.","date":"2024","source":"Journal, genetic engineering & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39674635","citation_count":5,"is_preprint":false},{"pmid":"38348042","id":"PMC_38348042","title":"Development and validation of a new diagnostic prediction model of ENHO and NOX4 for early diagnosis of systemic sclerosis.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38348042","citation_count":4,"is_preprint":false},{"pmid":"37688913","id":"PMC_37688913","title":"Adropin deficiency worsens TNBS-induced colitis.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37688913","citation_count":4,"is_preprint":false},{"pmid":"40097041","id":"PMC_40097041","title":"Adropin: A cardio-metabolic hormone in the periphery, a neurohormone in the brain?","date":"2025","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/40097041","citation_count":4,"is_preprint":false},{"pmid":"36326375","id":"PMC_36326375","title":"Evaluation of the relationship between vitamin D level and adropin, IL-1β, IL-6, and oxidative status in women.","date":"2022","source":"Turkish journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36326375","citation_count":4,"is_preprint":false},{"pmid":"38948172","id":"PMC_38948172","title":"Protective effect of ellagic acid against high-glucose-induced injury in human umbilical venous endothelial cells.","date":"2024","source":"Avicenna journal of phytomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/38948172","citation_count":3,"is_preprint":false},{"pmid":"40578684","id":"PMC_40578684","title":"Adropin expression reflects circadian, lipoprotein, and mitochondrial processes in human tissues.","date":"2025","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/40578684","citation_count":2,"is_preprint":false},{"pmid":"39933360","id":"PMC_39933360","title":"Adropin-Driven Browning: Targeting M2 Macrophages to Combat PCOS.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39933360","citation_count":2,"is_preprint":false},{"pmid":"40647442","id":"PMC_40647442","title":"The Role of ENHO in Pancreatic Adenocarcinoma: A Bioinformatics Approach.","date":"2025","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/40647442","citation_count":1,"is_preprint":false},{"pmid":"40999903","id":"PMC_40999903","title":"Single-cell transcriptomics reveals apolipoprotein A4-mediated metabolic-immune reprogramming in lymphocytes during early obesity-related chronic kidney disease.","date":"2025","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/40999903","citation_count":1,"is_preprint":false},{"pmid":"41391279","id":"PMC_41391279","title":"Protective effect of Adropin on sepsis-induced cardiomyopathy.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41391279","citation_count":0,"is_preprint":false},{"pmid":"41197826","id":"PMC_41197826","title":"Expression of adropin in the reproductive organs of healthy female dogs and those with cystic endometrial hyperplasia, pyometra, and ovarian cysts.","date":"2025","source":"Veterinary journal (London, England : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/41197826","citation_count":0,"is_preprint":false},{"pmid":"40176913","id":"PMC_40176913","title":"The potential of ARL4C and its-mediated genes in atherosclerosis and agent development.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40176913","citation_count":0,"is_preprint":false},{"pmid":"39948789","id":"PMC_39948789","title":"Time to broaden pharmacological treatment of cardiovascular disorders with physiological dimensions of Adropin.","date":"2025","source":"JPMA. The Journal of the Pakistan Medical Association","url":"https://pubmed.ncbi.nlm.nih.gov/39948789","citation_count":0,"is_preprint":false},{"pmid":"40903283","id":"PMC_40903283","title":"Development of a Specific Competitive ELISA for Plasma Adropin Levels and Its Application to Investigating Energy Homeostasis in Mice.","date":"2025","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/40903283","citation_count":0,"is_preprint":false},{"pmid":"41546878","id":"PMC_41546878","title":"Correlation between some hormones, interleukins and molecular parameters in rheumatoid arthritis patients with and without metabolic syndrome.","date":"2026","source":"The Egyptian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41546878","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33988,"output_tokens":6274,"usd":0.098037,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15305,"output_tokens":4877,"usd":0.099225,"stage2_stop_reason":"end_turn"},"total_usd":0.197262,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"ENHO encodes a secreted protein called adropin (76 amino acids) expressed in liver and brain. Liver Enho expression is regulated by nutrition (increased by high-fat diet acutely, decreased by fasting and diet-induced obesity). Transgenic overexpression or systemic adropin treatment in diet-induced obese mice attenuated hepatosteatosis and insulin resistance, and adropin regulated expression of hepatic lipogenic genes and adipose tissue PPARγ.\",\n      \"method\": \"Transgenic overexpression, systemic peptide treatment, gene expression analysis in mouse models\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — original discovery paper with multiple orthogonal methods (transgenic OE, peptide treatment, gene expression), replicated by subsequent independent studies\",\n      \"pmids\": [\"19041763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Adropin reduces paracellular permeability of brain endothelial cells exposed to ischemia-like conditions (hypoxia/low glucose) by inhibiting the ROCK–MLC2 signaling pathway. Adropin treatment concentration-dependently reduced MLC2 phosphorylation and attenuated Rho-associated kinase (ROCK) activity without protecting tight junction proteins (occludin, VE-cadherin) or reducing VEGF.\",\n      \"method\": \"In vitro BBB model (RBE4 rat brain endothelial cells), FITC-dextran permeability assay, ROCK activity assay, Western blot for MLC2 phosphorylation\",\n      \"journal\": \"Peptides\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean in vitro mechanistic dissection with multiple readouts in a single lab\",\n      \"pmids\": [\"27020249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Adropin knockout (AdrKO) mice exhibited reduced eNOS phosphorylation at Ser1177, impaired glycosphingolipid biosynthesis, adipocyte infiltration, loss of Treg cells, and developed fatty pancreas and type 2 diabetes, establishing that adropin deficiency drives these metabolic and immune phenotypes. A Cys56Trp mutation in ENHO was identified in human patients with fatty pancreas and T2DM.\",\n      \"method\": \"Adropin knockout mice (C57BL/6J), Western blot for phospho-eNOS, metabolic phenotyping, Treg quantification, human ENHO sequencing\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse model with multiple mechanistic readouts and human genetic validation, single lab\",\n      \"pmids\": [\"28837146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatic Enho expression is rhythmically controlled by the biological clock, peaking during feeding (dark phase) via transcriptional activation by RORα/γ, and suppressed during the rest phase by Rev-erb. ROR inverse agonists (SR1001), 7-oxygenated sterols (7-β-hydroxysterol, 7-ketocholesterol), and the Rev-erb agonist SR9009 suppress ENHO expression in cultured HepG2 cells. High-cholesterol diets suppress hepatic adropin expression, but adropin overexpression does not prevent hypercholesterolemia.\",\n      \"method\": \"In silico expression analysis, cultured human HepG2 cells treated with nuclear receptor ligands, animal dietary intervention, nonhuman primate plasma adropin profiling\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (cell culture, animal models, NHP) in single publication establishing circadian/nuclear receptor regulation\",\n      \"pmids\": [\"29331507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Adropin deficiency (AdrKO mice) leads to reduced eNOS (Ser1177) and Akt1 (Ser473) phosphorylation and loss of Treg cells, and homo- and heterozygous null mice exhibit MPO-ANCA-associated pulmonary alveolar hemorrhage. Six ENHO mutations (p.Ser43Thr, Cys56Trp) were identified in human MPO-ANCA vasculitis patients.\",\n      \"method\": \"Adropin knockout mice, Western blot for phospho-eNOS/Akt1, Treg analysis, human ENHO sequencing in 152 patients\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse with mechanistic phosphorylation readouts plus human genetic data, single lab\",\n      \"pmids\": [\"27333037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"EOGT (epidermal growth factor domain-specific O-linked GlcNAc transferase) positively regulates ENHO/adropin expression in decidualizing human endometrial stromal cells; EOGT knockdown caused the largest reduction in ENHO among a network of decidual genes. Obesity inversely correlates with both EOGT and ENHO expression in endometrium.\",\n      \"method\": \"EOGT siRNA knockdown in primary human endometrial stromal cells, RNA expression profiling, endometrial biopsy analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct knockdown experiment identifying upstream regulator of ENHO, single lab with in vitro and human tissue validation\",\n      \"pmids\": [\"29244071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Adropin stimulates proliferation of 3T3-L1 cells and rat primary preadipocytes via ERK1/2 and AKT signaling, and reduces lipid accumulation and expression of pro-adipogenic genes, suppressing differentiation of preadipocytes into mature fat cells.\",\n      \"method\": \"3T3-L1 cell and rat primary preadipocyte cultures, BrdU proliferation assay, Oil Red O lipid staining, Western blot for ERK1/2 and AKT phosphorylation, real-time PCR for adipogenic gene expression\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean in vitro mechanistic dissection with multiple readouts in two cell models, single lab\",\n      \"pmids\": [\"31400396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GPR19 is expressed in human HAC15 adrenocortical carcinoma cells and mediates adropin signaling. Adropin decreases expression of steroidogenic genes (StAR, CYP11A1), leading to reduced cortisol and aldosterone biosynthesis via the TGF-β signaling pathway acting through a transactivation mechanism. Adropin stimulates HAC15 cell proliferation via ERK1/2 and AKT signaling pathways. GPR19 expression is not regulated by ACTH, forskolin, or adropin itself.\",\n      \"method\": \"HAC15 cell culture, GPR19 expression analysis, steroidogenesis assays (ELISA for cortisol/aldosterone), whole transcriptome study, TGF-β receptor kinase inhibitor rescue experiment, specific intracellular inhibitors for ERK1/2 and AKT\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods in single lab identifying receptor, pathway, and functional outcomes\",\n      \"pmids\": [\"33133015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"STAT3 transcriptionally regulates ENHO/adropin expression in hepatocytes. High glucose increased STAT3 phosphorylation and Enho mRNA in HepG2 cells; pharmacological STAT3 inhibition (Stattic) or STAT3 siRNA knockdown abolished high-glucose-induced Enho upregulation. In diabetic rats, elevated plasma adropin and hepatic Enho expression were reduced by insulin or phloridzin treatment coinciding with reduced STAT3 activity.\",\n      \"method\": \"HepG2 cells under high glucose, STAT3 inhibitor (Stattic), STAT3 siRNA knockdown, real-time PCR for Enho mRNA, Western blot for pSTAT3/STAT3, streptozotocin diabetic rat model\",\n      \"journal\": \"Diabetes, metabolic syndrome and obesity : targets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic (siRNA) inhibition of STAT3 with consistent results in vitro and in vivo, single lab\",\n      \"pmids\": [\"32636661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Adropin stimulates proliferation of rat brown preadipocytes and suppresses their differentiation into mature brown adipocytes, reducing mRNA expression of adipogenic genes (C/ebpα, C/ebpβ, Pgc1α, Pparγ, Prdm16), suppressing UCP1 protein, and reducing intracellular lipid content.\",\n      \"method\": \"Rat primary brown preadipocyte isolation, BrdU incorporation, real-time PCR, Western blot, Oil Red O staining, glycerol/free fatty acid release assays\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal readouts in primary cells, single lab, consistent with findings in white preadipocytes\",\n      \"pmids\": [\"32798458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Genetic deletion of Enho significantly increased infarct volume and worsened neurological function following transient middle cerebral artery occlusion in aged mice, while adropin overexpression dramatically reduced stroke volume. Postischemic adropin treatment reduced blood-brain barrier damage by reducing MMP-9 and preserving tight junction proteins.\",\n      \"method\": \"Enho knockout and overexpression mice, transient MCAO model, TTC staining, Western blot for MMP-9 and tight junction proteins, behavioral tests\",\n      \"journal\": \"Stroke\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — both loss-of-function (KO) and gain-of-function (OE and peptide treatment) with consistent mechanistic readouts replicated across multiple experimental arms\",\n      \"pmids\": [\"36305313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Hepatic adropin/Enho expression is regulated by estrogen; 17β-estradiol tripled Enho expression in BNL 1 ME liver cells with increased adropin secretion. Ovariectomy reduced hepatic Enho expression in mice, and open-access datasets confirmed estrogen-dependent ERα binding to Enho. Adropin treatment in OVX mice reversed adverse adipokine gene expression in visceral adipose tissue.\",\n      \"method\": \"Ovariectomy mouse model, in vitro 17β-estradiol treatment of liver cells, RNA-seq, ELISA for adropin, open-access ChIP dataset for ERα binding, adropin peptide treatment\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo experiments with ChIP confirmation of ERα binding to Enho, single lab\",\n      \"pmids\": [\"35364299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Adropin inhibits EndMT (endothelial-to-mesenchymal transition) in HUVECs via the TGF-β/Smad2/3 signaling pathway. In vivo, adropin treatment inhibited atherosclerosis progression in ApoE-/-/Enho-/- mice. Adropin decreased TGF-β1 and TGF-β2 expression and suppressed Smad2/3 phosphorylation; these effects were reversed by TGF-β plasmid transfection.\",\n      \"method\": \"ApoE-/-/Enho-/- double knockout mice, HFD atherosclerosis model, Oil Red O staining, HUVEC culture with H2O2-induced EndMT, TGF-β plasmid transfection rescue, Western blot for Smad2/3 phosphorylation, immunofluorescence\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic rescue experiment and in vivo double KO model, single lab\",\n      \"pmids\": [\"37903785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TGFβ reduces adropin/ENHO expression in fibroblasts via a JNK-dependent mechanism. Restoration of adropin signaling with bioactive adropin34-76 peptide inhibits TGFβ-induced fibroblast activation and fibrotic remodeling. Knockdown of GPR19 (adropin receptor) abrogates the antifibrotic effects. RNA-seq and ChIP-seq showed adropin34-76 deactivates GLI1-dependent profibrotic transcriptional networks. These mechanisms were confirmed in primary human dermal fibroblasts, 3D skin equivalents, mouse models (bleomycin and sclGvHD), and precision-cut human skin slices.\",\n      \"method\": \"GPR19 siRNA knockdown, RNA-seq, ChIP-seq, in vitro fibroblast cultures, 3D skin equivalents, bleomycin and sclGvHD mouse models, precision-cut human skin slices, JNK inhibitor experiments\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (RNA-seq, ChIP-seq, receptor KD, multiple in vivo models, human tissue), replicated across multiple experimental systems in one rigorous study\",\n      \"pmids\": [\"38536934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Adropin deficiency (Enho-/- mice) leads to spontaneous colitis and an imbalance in macrophage polarization (increased M1, decreased M2) in colon and mesenteric tissues. In vitro, adropin regulates lipid metabolism of macrophages through PPARγ, promoting repolarization from M1 to M2. This was demonstrated by combined RNA-seq and metabolomics analysis in RAW264.7 macrophages.\",\n      \"method\": \"Enho-/- (AdrKO) mice, TNBS-induced colitis model, RNA-seq and metabolomics of RAW264.7 macrophages, macrophage polarization assays\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout mouse with in vitro mechanistic follow-up using two omics approaches, single lab\",\n      \"pmids\": [\"37688913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Low-dose adropin (<100 ng/mL) directly increases mitochondrial reactive oxygen species in macrophages to activate the inflammasome, promoting M1 macrophage polarization. High-dose adropin enhances CPT1α expression in macrophages. ENHO-/- mice had fewer M1 macrophages, and ENHO-/- macrophages were resistant to M1 induction. ENHO gene transfection into MC38 colon cancer cells inhibited tumor growth in vivo with increased M1 macrophages.\",\n      \"method\": \"Ex vivo macrophage adropin treatment, mitochondrial ROS measurement, inflammasome activation assays, ENHO-/- mice, ENHO gene transfection into MC38 tumor cells, in vivo tumor models\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both in vitro mechanistic data and KO mouse validation with multiple readouts, single lab\",\n      \"pmids\": [\"37904094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Myricetin increases circulating adropin in type-1 diabetic rats through GLP-1 receptor activation leading to β-endorphin secretion that activates peripheral μ-opioid receptors; GLP-1 receptor antagonist blocked myricetin-induced adropin increases. In HepG2 cells, myricetin-induced GLP-1 receptor activation modulated Enho expression.\",\n      \"method\": \"Streptozotocin diabetic rat model, GLP-1 receptor antagonist treatment, adrenalectomy, ELISA for plasma adropin and β-endorphin, qPCR for Enho in HepG2 cells\",\n      \"journal\": \"Pharmaceuticals (Basel, Switzerland)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological intervention study with indirect pathway inferences, single lab, mechanistic chain not directly confirmed\",\n      \"pmids\": [\"35215286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In mouse testis, adropin alone inhibits testosterone synthesis by suppressing P450-SCC, 3β-HSD, and 17β-HSD expression, while adropin combined with insulin stimulates testicular testosterone synthesis by increasing GPR19, IR, StAR, P450-SCC, 3β-HSD, and 17β-HSD expression. Adropin promotes germ cell survival and proliferation by upregulating PCNA, Bcl2, and pERK1/2. GPR19 was identified on pachytene spermatocytes and Leydig cells.\",\n      \"method\": \"Immunohistochemistry for adropin/GPR19 in mouse testis, in vitro testicular slice culture, Western blot for steroidogenic enzymes and signaling proteins, Enho mRNA expression\",\n      \"journal\": \"Journal of experimental zoology. Part A, Ecological and integrative physiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vitro testicular slice culture with protein expression readouts, single lab, no receptor-specific antagonist controls\",\n      \"pmids\": [\"37902254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Adropin exerts protective effects in LPS-induced septic cardiomyopathy by activating the Nrf2/ARE signaling pathway, increasing antioxidant proteins (NQO1, GPX1, Nrf2), reducing ROS, and suppressing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and apoptosis (reduced Bax, increased Bcl-2). The Nrf2 inhibitor ML385 blocked adropin's antioxidant effects.\",\n      \"method\": \"LPS mouse model of myocardial injury, Nrf2 inhibitor (ML385) rescue experiment, qRT-PCR, Western blot, DHE staining and flow cytometry for ROS, echocardiography\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological rescue with Nrf2 inhibitor identifies mechanistic pathway, multiple readouts, single lab\",\n      \"pmids\": [\"41391279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Adropin promotes macrophage M2 polarization by upregulating heme oxygenase-1 (HO-1), and adropin-treated macrophage-conditioned medium induces browning of fully differentiated 3T3-L1 adipocytes. In PCOS model mice, adropin treatment reduced body weight and promoted M2 macrophage phenotype and white adipose tissue browning.\",\n      \"method\": \"RAW264.7 macrophage HO-1 expression analysis, conditioned medium transfer to 3T3-L1 adipocytes, letrozole-induced PCOS mouse model, in vivo adropin injection\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — conditioned medium approach is indirect, single lab, HO-1 mechanistic link not confirmed by loss-of-function\",\n      \"pmids\": [\"39933360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ENHO/adropin transcriptional co-expression structures across human tissues revealed that liver ENHO expression co-regulates skeletal muscle mitochondrial function (confirmed in liver-specific knockout mice). Within-liver ENHO expression reflects lipoprotein metabolism (APOC1, APOA1). Statin treatment (which increases hepatic cholesterol efflux) reduces plasma adropin levels. The ENHO gene contains RORE elements, linking it to circadian/ROR regulation across tissues.\",\n      \"method\": \"Transcriptomic correlation analysis across human tissues (GD-CAT), liver-specific knockout mice, plasma adropin/lipoprotein correlation, statin-treatment experiment\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — liver-specific KO confirms functional co-regulation; correlational analyses and statin experiment in single publication\",\n      \"pmids\": [\"40578684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Hepatic ENHO expression in nonhuman primates associates with genes involved in glucose and lipid metabolism, and co-regulated genes are enriched for epigenetic silencing by histone H3K27 trimethylation and neural function pathways. Low plasma adropin concentrations predict greater weight gain and metabolic dysregulation (hyperglycemia, elevated APOC3/triglycerides) during high-sugar diet consumption.\",\n      \"method\": \"In silico expression profiling (diurnal transcriptome atlas GSE98965), unsupervised hierarchical clustering, Gene Ontology analysis, dietary intervention in 59 adult male rhesus macaques\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — primarily bioinformatic with correlational animal intervention; no direct mechanistic experiment on ENHO protein function\",\n      \"pmids\": [\"30988006\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ENHO encodes adropin, a secreted peptide hormone (active form adropin34-76) that signals through the GPR19 receptor to regulate energy homeostasis: adropin is transcriptionally controlled by circadian nuclear receptors (RORα/γ activates, Rev-erb represses), STAT3, estrogen (ERα), and nutrients (high-fat/sugar diet, cholesterol); it attenuates hepatic lipogenesis and insulin resistance, reduces blood-brain barrier permeability via ROCK–MLC2 inhibition, suppresses preadipocyte differentiation via ERK1/2/AKT, inhibits fibroblast activation by deactivating GLI1-dependent profibrotic transcription downstream of GPR19 (counteracting TGFβ–JNK-mediated ENHO suppression), promotes macrophage M1→M2 repolarization through PPARγ-mediated lipid metabolism, and protects against ischemic stroke and septic cardiomyopathy partly through eNOS phosphorylation and Nrf2/ARE antioxidant pathways.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ENHO encodes adropin, a secreted peptide hormone (active form adropin34-76) that regulates energy homeostasis and protects against metabolic and inflammatory tissue injury [#0, #13]. Hepatic Enho expression is nutritionally and hormonally gated: it is induced acutely by high-fat diet and reduced by fasting and diet-induced obesity [#0], driven rhythmically by the circadian nuclear receptors ROR\\u03b1/\\u03b3 (activating) and Rev-erb (repressing) [#3], and additionally controlled by STAT3 under high glucose [#8], by estrogen via ER\\u03b1 binding to Enho [#11], and by EOGT in decidualizing endometrium [#5]; high-cholesterol diet and statin-driven cholesterol efflux suppress it [#3, #20]. Functionally, adropin overexpression or peptide treatment attenuates hepatosteatosis and insulin resistance and reprograms hepatic lipogenic and adipose PPAR\\u03b3 gene expression [#0], and liver ENHO co-regulates skeletal-muscle mitochondrial function [#20]. Adropin signals through the receptor GPR19 [#7, #13]: it deactivates GLI1-dependent profibrotic transcription to block TGF\\u03b2-driven fibroblast activation, counteracting JNK-mediated suppression of its own gene [#13], suppresses preadipocyte differentiation while stimulating proliferation via ERK1/2 and AKT [#6, #9], and reprograms macrophage polarization through PPAR\\u03b3-linked lipid metabolism [#14]. It is cytoprotective in ischemic stroke, where Enho deletion enlarges infarcts and adropin preserves blood-brain barrier integrity by inhibiting ROCK\\u2013MLC2 signaling and reducing MMP-9 [#1, #10], and in septic cardiomyopathy via the Nrf2/ARE antioxidant axis [#18]. Loss-of-function in mice produces fatty pancreas, type 2 diabetes, reduced eNOS Ser1177 phosphorylation, and immune dysregulation, and ENHO coding mutations were identified in human patients with fatty pancreas/T2DM and with MPO-ANCA vasculitis [#2, #4].\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established that ENHO encodes a secreted, nutritionally regulated peptide hormone (adropin) controlling hepatic lipid metabolism and insulin sensitivity, defining the gene's core physiological role.\",\n      \"evidence\": \"Transgenic overexpression, systemic peptide treatment, and hepatic/adipose gene expression analysis in diet-induced obese mice\",\n      \"pmids\": [\"19041763\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and direct signaling mechanism not identified\", \"Tissue source of circulating adropin beyond liver not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified a vascular-protective mechanism distinct from metabolic action, showing adropin reduces brain endothelial permeability under ischemic conditions via ROCK\\u2013MLC2 inhibition.\",\n      \"evidence\": \"In vitro RBE4 rat brain endothelial BBB model, FITC-dextran permeability, ROCK activity assay, MLC2 phospho-Western blot\",\n      \"pmids\": [\"27020249\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating the effect not defined\", \"No in vivo confirmation in this study\", \"Did not affect tight junction proteins or VEGF, leaving upstream coupling unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked adropin deficiency to eNOS/Akt signaling and immune dysregulation, and connected ENHO coding variants to human autoimmune vasculitis.\",\n      \"evidence\": \"Adropin knockout mice with phospho-eNOS/Akt1 Westerns, Treg analysis, and ENHO sequencing in 152 MPO-ANCA patients\",\n      \"pmids\": [\"27333037\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality of human variants not functionally tested\", \"Mechanism linking adropin loss to autoimmunity not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that adropin deficiency drives a metabolic-disease phenotype (fatty pancreas, T2DM) and identified a human ENHO mutation in affected patients.\",\n      \"evidence\": \"AdrKO mice with metabolic phenotyping, phospho-eNOS Western, Treg quantification, and human ENHO sequencing\",\n      \"pmids\": [\"28837146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cys56Trp mutation not functionally characterized\", \"Single-lab phenotype\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined the upstream transcriptional logic of ENHO, placing it under circadian nuclear-receptor control (ROR activation, Rev-erb repression) and sterol/cholesterol regulation.\",\n      \"evidence\": \"HepG2 cells treated with nuclear-receptor ligands, dietary intervention, and nonhuman-primate plasma profiling\",\n      \"pmids\": [\"29331507\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RORE occupancy at the endogenous locus not shown here\", \"Physiological consequence of rhythmicity not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed adropin acts directly on adipocyte precursors, stimulating proliferation via ERK1/2/AKT while suppressing adipogenic differentiation.\",\n      \"evidence\": \"3T3-L1 and rat primary preadipocyte cultures, BrdU, Oil Red O, ERK1/2/AKT Westerns, adipogenic gene qPCR\",\n      \"pmids\": [\"31400396\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor not identified in these cells\", \"In vivo relevance to adipose mass not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Associated hepatic ENHO with glucose/lipid metabolic gene networks and showed low plasma adropin predicts diet-induced metabolic dysregulation.\",\n      \"evidence\": \"Bioinformatic expression profiling and dietary intervention in rhesus macaques\",\n      \"pmids\": [\"30988006\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Correlational/bioinformatic; no direct manipulation of ENHO\", \"Causality of plasma adropin as predictor unestablished\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified GPR19 as the receptor mediating adropin signaling and demonstrated adropin suppresses steroidogenesis via TGF-\\u03b2 transactivation while driving proliferation through ERK1/2/AKT.\",\n      \"evidence\": \"HAC15 adrenocortical cells, GPR19 expression, steroidogenesis ELISAs, transcriptomics, TGF-\\u03b2 kinase inhibitor and ERK/AKT inhibitor experiments\",\n      \"pmids\": [\"33133015\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct adropin\\u2013GPR19 binding not demonstrated\", \"Generalizability of receptor coupling to other tissues not shown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Added STAT3 and estrogen/ER\\u03b1 as upstream regulators of hepatic ENHO, linking adropin output to glucose state and hormonal status.\",\n      \"evidence\": \"HepG2 high-glucose STAT3 inhibition/siRNA with diabetic rats; ovariectomy mice, 17\\u03b2-estradiol on liver cells, RNA-seq, ER\\u03b1 ChIP datasets\",\n      \"pmids\": [\"32636661\", \"35364299\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT3 occupancy at ENHO promoter not mapped in first study\", \"Integration of competing transcriptional inputs not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established a causal protective role for ENHO in ischemic stroke through both loss- and gain-of-function, acting on blood-brain barrier integrity.\",\n      \"evidence\": \"Enho knockout and overexpression mice in transient MCAO, TTC staining, MMP-9 and tight-junction Westerns, behavioral testing\",\n      \"pmids\": [\"36305313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating neuroprotection not defined in vivo\", \"Relationship to the earlier ROCK\\u2013MLC2 mechanism not directly tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed adropin as an immunometabolic regulator of macrophage polarization, promoting M1\\u2192M2 repolarization through PPAR\\u03b3-linked lipid metabolism with dose-dependent inflammasome effects.\",\n      \"evidence\": \"Enho-/- colitis and tumor models, RNA-seq/metabolomics in RAW264.7 macrophages, mitochondrial ROS and inflammasome assays, ENHO transfection into MC38 cells\",\n      \"pmids\": [\"37688913\", \"37904094\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dose-dependent opposing effects on M1 vs M2 not mechanistically reconciled\", \"Receptor dependence of macrophage effects not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed adropin restrains TGF-\\u03b2/Smad2/3-driven endothelial-to-mesenchymal transition and atherosclerosis progression.\",\n      \"evidence\": \"ApoE-/-/Enho-/- mice, HUVEC EndMT model, TGF-\\u03b2 plasmid rescue, Smad2/3 phospho-Westerns\",\n      \"pmids\": [\"37903785\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor not interrogated\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined the antifibrotic mechanism at the transcriptional level, showing GPR19-dependent adropin34-76 deactivates GLI1 profibrotic networks while TGF\\u03b2 suppresses ENHO via JNK, establishing a feedback circuit.\",\n      \"evidence\": \"GPR19 siRNA knockdown, RNA-seq, ChIP-seq, human fibroblasts, 3D skin equivalents, bleomycin/sclGvHD mouse models, precision-cut human skin slices, JNK inhibitor experiments\",\n      \"pmids\": [\"38536934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct adropin\\u2013GPR19\\u2013GLI1 biochemical link not fully resolved\", \"Translation to systemic fibrosis beyond skin not shown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended adropin's protective repertoire to septic cardiomyopathy via the Nrf2/ARE antioxidant pathway.\",\n      \"evidence\": \"LPS mouse myocardial injury, Nrf2 inhibitor (ML385) rescue, ROS staining/flow cytometry, echocardiography\",\n      \"pmids\": [\"41391279\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor coupling to Nrf2 not defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected hepatic ENHO to systemic mitochondrial and lipoprotein metabolism, with liver-specific knockout confirming cross-tissue muscle regulation.\",\n      \"evidence\": \"Cross-tissue transcriptomic correlation (GD-CAT), liver-specific knockout mice, plasma adropin/lipoprotein correlation, statin experiment\",\n      \"pmids\": [\"40578684\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mediator of liver-to-muscle communication not identified\", \"Correlational human data\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single secreted peptide acting through GPR19 produces context- and dose-dependent outcomes across metabolic, vascular, fibrotic, and immune tissues remains unresolved, as does the structural basis of adropin\\u2013GPR19 engagement.\",\n      \"evidence\": \"No direct ligand-receptor structural or binding study present in the corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of adropin or adropin\\u2013GPR19 complex\", \"Mechanism reconciling opposing dose-dependent immune effects unknown\", \"Whether all downstream pathways (ROCK, Nrf2, PPAR\\u03b3, GLI1) require GPR19 untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 7, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 6, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14, 15]},\n      {\"term_id\": \"R-HSA-9909396\", \"supporting_discovery_ids\": [3, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GPR19\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}